Status:
COMPLETED
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Pneumonia, Pneumocystis Carinii
HIV Infections
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with advanced HIV disease and T4 cell count \< 200 cells/mm3. To establish the range of pentamidine (PEN) depositi...
Detailed Description
The specific system that is used to deliver PEN to the lungs may determine whether a therapeutically effective dose is attained in the lungs. Therefore, this study will establish the amount of PEN tha...
Eligibility Criteria
Inclusion Criteria
Concurrent Treatment:
Allowed:
- Local radiation for Kaposi's sarcoma.
Patients who successfully completed a course of study therapy for acute Pneumocystis carinii pneumonia (PCP) and who met the inclusion criteria for Protocol ACTG 021 or ACTG 081 and were randomized to the aerosolized pentamidine arm.
- Patients who are currently receiving aerosolized pentamidine as prophylactic therapy for PCP.
Exclusion Criteria
The following patients are excluded:
- Those enrolled in ACTG 021 and randomized to the oral prophylaxis arm.
- Those enrolled in ACTG 081 and randomized to the trimethoprim / sulfamethoxazole and dapsone arms.
Prior Treatment:
Excluded within 2 weeks of study entry:
- Transfusions of blood or red blood cells.
Co-Existing Condition:
- Significant adverse effects.
Active substance abuse.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
January 1 1992
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00001003
End Date
January 1 1992
Last Update
November 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SUNY - Stony Brook
Stony Brook, New York, United States, 11794